Induction chemotherapy with docetaxel and doxorubicin followed by proton beam radiation therapy for platinum-resistant unresectable sinonasal undifferentiated carcinoma

Sinonasal undifferentiated carcinoma is a rare and aggressive tumor with an extremely poor prognosis. In the vast majority of cases, this tumor can not be resected due to its rapid local growth. Correct morphological diagnosis is impossible without a thorough differential diagnosis between sinonasal undifferentiated carcinoma and a number of lowgrade tumors of the nasal cavity and paranasal sinuses. Very few case reports and retrospective studies on sinonasal undifferentiated carcinoma have been published so far. No unified widely accepted guidelines on sinonasal undifferentiated carcinoma treatment are currently available due to the lack of statistically significant data from randomized clinical trials. The optimal treatment strategy should be based on an aggressive multimodal approach involving radical surgery, precision radiation therapy, and intensive chemotherapy. The benefits of systemic targeted therapy for patients with sinonasal undifferentiated carcinoma are still unclear. The best results can be achieved by employing tailored treatment approaches preferably in multidisciplinary cancer centers, where healthcare professionals experienced in managing patients with head and neck tumors can be involved. In this article, we report a case of complete radiological response after induction chemotherapy with docetaxel and doxorubicin and proton radiation therapy for the primary tumor area in a 53‑year-old female patient with non-resectable platinum-resistant sinonasal undifferentiated carcinoma.

Download Full-text

Sinonasal undifferentiated carcinoma with skull-base invasion treated with induction chemotherapy and concurrent chemoradiotherapy consisting of cisplatin plus etoposide

JOURNAL OF JAPAN SOCIETY FOR HEAD AND NECK SURGERY ◽

10.5106/jjshns.30.359 ◽

2020 ◽

Vol 30 (3) ◽

pp. 359-366

Author(s):

Ichiro Tojima ◽

Takuya Murao ◽

Sayuri Yamamoto ◽

Takeshi Shimizu

Keyword(s):

Skull Base ◽

Induction Chemotherapy ◽

Concurrent Chemoradiotherapy ◽

Undifferentiated Carcinoma ◽

Sinonasal Undifferentiated Carcinoma

Download Full-text

Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2019.03.049 ◽

2019 ◽

Vol 104 (5) ◽

pp. 1057-1065 ◽

Cited By ~ 3

Author(s):

Christopher L. Hallemeier ◽

Peixin Zhang ◽

Thomas M. Pisansky ◽

Gerald E. Hanks ◽

David G. McGowan ◽

...

Keyword(s):

Radiation Therapy ◽

Randomized Clinical Trials ◽

Radiation Therapy Oncology Group ◽

Specific Antigen ◽

Pooled Analysis ◽

External Beam Radiation Therapy ◽

External Beam Radiation ◽

Short Term ◽

Beam Radiation ◽

Androgen Suppression

Download Full-text

The role of radiosurgery in the management of WHO Grade II and III intracranial meningiomas

Neurosurgical FOCUS ◽

10.3171/2013.9.focus13364 ◽

2013 ◽

Vol 35 (6) ◽

pp. E16 ◽

Cited By ~ 24

Author(s):

Dale Ding ◽

Robert M. Starke ◽

John Hantzmon ◽

Chun-Po Yen ◽

Brian J. Williams ◽

...

Keyword(s):

Radiation Therapy ◽

Stereotactic Radiosurgery ◽

Case Reports ◽

Case Series ◽

External Beam Radiation ◽

Beam Radiation ◽

Who Grade ◽

Intracranial Meningiomas ◽

Grade Ii ◽

Grade Iii

Object WHO Grade II and III intracranial meningiomas are uncommon, but they portend a significantly worse prognosis than their benign Grade I counterparts. The mainstay of current management is resection to obtain cytoreduction and histological tissue diagnosis. The timing and benefit of postoperative fractionated external beam radiation therapy and stereotactic radiosurgery remain controversial. The authors review the stereotactic radiosurgery outcomes for Grade II and III meningiomas. Methods A comprehensive literature search was performed using PubMed to identify all radiosurgery series reporting the treatment outcomes for Grade II and III meningiomas. Case reports and case series involving fewer than 10 patients were excluded. Results From 1998 to 2013, 19 radiosurgery series were published in which 647 Grade II and III meningiomas were treated. Median tumor volumes were 2.2–14.6 cm3. The median margin doses were 14–21 Gy, although generally the margin doses for Grade II meningiomas were 16–20 Gy and the margin doses for Grade III meningiomas were 18–22 Gy. The median 5-year PFS was 59% for Grade II tumors and 13% for Grade III tumors, which may have been affected by patient age, prior radiation therapy, tumor volume, and radiosurgical dose and timing. The median complication rate following radiosurgery was 8%. Conclusions The current data for radiosurgery suggest that it has a role in the management of residual or recurrent Grade II and III meningiomas. However, better studies are needed to fully define this role. Due to the relatively low prevalence of these tumors, it is unlikely that prospective studies will be feasible. As such, well-designed retrospective analyses may improve our understanding of the effect of radiosurgery on tumor recurrence and patient survival and the incidence and impact of treatment-induced complications.

Download Full-text